Literature DB >> 18797432

A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it?

Keith A A Fox1, Kurt Huber.   

Abstract

For the management of ST-segment elevation acute myocardial infarction (STEMI), international guidelines recommend primary percutaneous coronary intervention with adjunctive antithrombotic therapy, the management of complications, and secondary prevention measures. Delivery of care has, however, lagged behind establishing the evidence for effectiveness. Approximately a quarter of all patients with STEMI still fail to receive reperfusion therapy. Additionally, for most patients delays substantially exceed guideline recommendations and secondary prevention is incomplete. What can be done? First, cardiologists need to take the lead in improving systems of care, with the integration of prehospital care within 'heart attack networks' involving intervention centers, nonintervention hospitals, primary care, and paramedic ambulance care. Several examples show that such systems are feasible. 'Door-to-balloon' initiatives can improve care in the final interventional hospital, but only make a modest contribution to total patient delay. Second, high-risk patients, including the elderly and those with cardiac complications like heart failure, should be targeted for more-aggressive interventional and pharmacologic therapy; the opposite situation currently exists in clinical practice (the treatment-risk paradox). Third, greater emphasis on quality improvement, collaboration among health professionals, and achieving high-quality care for all is required from funding bodies, regulatory agencies and professional societies.

Entities:  

Mesh:

Year:  2008        PMID: 18797432     DOI: 10.1038/ncpcardio1343

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  5 in total

1.  One-year mortality in patients with acute ST-elevation myocardial infarction in the Vienna STEMI registry.

Authors:  Bernhard Jäger; Serdar Farhan; Karim Kalla; Helmut D Glogar; Günter Christ; Ronald Karnik; Georg Norman; Herbert Prachar; Wolfgang Schreiber; Alfred Kaff; Andrea Podczeck-Schweighofer; Franz Weidinger; Thomas Stefenelli; Georg Delle-Karth; Anton N Laggner; Gerald Maurer; Kurt Huber
Journal:  Wien Klin Wochenschr       Date:  2015-07-11       Impact factor: 1.704

2.  Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective.

Authors:  Frederick A Spencer; Gilles Montalescot; Keith A A Fox; Shaun G Goodman; Christopher B Granger; Robert J Goldberg; Gustavo B F Oliveira; Frederick A Anderson; Kim A Eagle; Gordon Fitzgerald; Joel M Gore
Journal:  Eur Heart J       Date:  2010-03-15       Impact factor: 29.983

3.  Exploring the treatment delay in the care of patients with ST-elevation myocardial infarction undergoing acute percutaneous coronary intervention: a cross-sectional study.

Authors:  Joppe Tra; Ineke van der Wulp; Martine C de Bruijne; Cordula Wagner
Journal:  BMC Health Serv Res       Date:  2015-08-21       Impact factor: 2.655

4.  The prognosis of primary percutaneous coronary intervention after one year clinical follow up.

Authors:  Yahya Dadjoo; Yadallah Mahmoodi
Journal:  Int Cardiovasc Res J       Date:  2013-03-15

5.  Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries.

Authors:  Petr Widimsky; William Wijns; Jean Fajadet; Mark de Belder; Jiri Knot; Lars Aaberge; George Andrikopoulos; Jose Antonio Baz; Amadeo Betriu; Marc Claeys; Nicholas Danchin; Slaveyko Djambazov; Paul Erne; Juha Hartikainen; Kurt Huber; Petr Kala; Milka Klinceva; Steen Dalby Kristensen; Peter Ludman; Josephina Mauri Ferre; Bela Merkely; Davor Milicic; Joao Morais; Marko Noc; Grzegorz Opolski; Miodrag Ostojic; Dragana Radovanovic; Stefano De Servi; Ulf Stenestrand; Martin Studencan; Marco Tubaro; Zorana Vasiljevic; Franz Weidinger; Adam Witkowski; Uwe Zeymer
Journal:  Eur Heart J       Date:  2009-11-19       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.